Browsing Category
Pharma Industry News
4750 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Sanofi to acquire Vigil Neuroscience for $470m to advance TREM2-targeting Alzheimer’s therapy
Sanofi to acquire Vigil Neuroscience for $470M, aiming to add VG-3927, a TREM2-based Alzheimer’s drug, to its neurology pipeline.
Phase 3 trials to watch in 2025: Why this year matters for biotech investors
Explore the top Phase 3 trials of 2025 from Eli Lilly, GSK, and Innovent Biologics — including pipeline impact, investor sentiment, and regulatory milestones.
Cytosorbents reports breakthrough real-world data on reducing bleeding in CABG patients on ticagrelor using CytoSorb therapy at EuroPCR 2025
New real-world data from EuroPCR 2025 shows CytoSorb® significantly reduces bleeding in CABG patients on ticagrelor. Read the full clinical findings.
Dimerix stock up 74% YTD as FSGS asset DMX-200 gets safety green light
Dimerix’s FSGS drug candidate DMX-200 clears key Phase 3 safety review with no concerns. Learn how this ASX biotech aims to reshape kidney disease treatment.
Is AFT Pharmaceuticals undervalued after NZ$208m in FY25 Revenue? What’s next for AFP stock
AFT Pharmaceuticals posts NZ$208M record revenue in FY25. Find out why investors are eyeing its NZ$300M growth target despite short-term profit dips.
Sarepta’s gene therapy marches on: UK clears continued dosing in Duchenne Phase 3 trial
Find out how Sarepta Therapeutics is advancing Duchenne gene therapy with UK backing for its ENVISION trial of ELEVIDYS in non-ambulatory patients.
Lupin to launch India’s first green inhalers with Honeywell’s Solstice Air: Can pharma go climate-smart?
Lupin is partnering with Honeywell to launch India’s first low-GWP inhalers using Solstice Air propellant. Find out how it’s reshaping respiratory care.
Cybin backs FDA’s call to fast-track psychedelic therapeutics as CYB003 advances in Phase 3 trials
Cybin welcomes FDA’s call to fast-track psychedelics for mental health. See how CYB003 is advancing in Phase 3 trials for depression treatment.
PepGen brings in gene therapy veteran to accelerate breakthrough neuromuscular treatments
PepGen names gene therapy veteran Kasra Kasraian as CTO to scale up oligonucleotide therapies for neuromuscular diseases. Find out what this means for investors.
Viridian Therapeutics reports 70% durability at one year in Phase 3 THRIVE trial for veligrotug in thyroid eye disease
Viridian's veligrotug maintained a 70% response at 52 weeks in TED patients; BLA filing expected in H2 2025. Find out how this breakthrough could reshape care.